Martinez-Valbuena, Ivan
Swinkin, Emily
Santamaria, Enrique
Fernandez-Irigoyen, Joaquin
Sackmann, Valerie
Kim, Ain
Li, Jun
Gonzalez-Latapi, Paulina
Kuhlman, Greg
Bhowmick, Suvorit Subhas
Visanji, Naomi P.
Lang, Anthony E.
Kovacs, Gabor G. http://orcid.org/0000-0003-3841-5511
Funding for this research was provided by:
Edmond J. Safra Philanthropic Foundation
Rossy Foundation
Maybank Foundation
Blidner Family Foundation
Canadian Foundation for Innovation (John R. Evans Leaders Fund (40480))
Ontario Research Fund for Small Infrastructure Funds
Spanish Ministry of Science Innovation and Universities (PID2019-110356RB-I00/AEI/10.13039/501100011033, PID2019-110356RB-I00/AEI/10.13039/501100011033)
Article History
Received: 20 April 2022
Revised: 7 June 2022
Accepted: 7 June 2022
First Online: 24 June 2022
Declarations
:
: Gabor G. Kovacs is member of the Acta Neuropathologica Editorial Board but was not involved in the editorial handling of this article. GGK holds a shared patent for the 5G4 synuclein antibody.